Introduction to Trials Demonstrate

Background Recently, two randomized controlled trials demonstrated the benefit of mechanical thrombectomy performed between 6 and 24 h in acute ischemic stroke.

In 2015, several published clinical trials demonstrated the value of mechanical thrombectomy (MT) for patients with acute ischemic stroke and evidence.

Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approximately 3 months in patients with advanced HCC compared with placebo.

Clinical trials demonstrated that addition of Beva to chemotherapy improved overall survival (OS) by 12months compared with placebo, and recent results are even more promising [3].

Clinical trials demonstrate that the use of anti-VEGF helps stabilize the vision in at least 90 % of patients, while 30 to 40 % gain three or more lines of vision (15 ETDRS letters).

The results of antibacterial tests and clinical trials demonstrated the excellent antibacterial power of 5%QAS-c-PMMA.

Two recent randomized controlled trials demonstrated improved radiographic, histological and hepatometabolic cues of non-alcoholic steatohepatitis (NASH) in pediatric patients treated with the ω-3 fatty acid docosahexaenoic acid (DHA) in combination with vitamin D (VD) or with choline (CHO) and vitamin E (VE), the DHA-VD and DHA-CHO-VE trials, respectively).

Post hoc analyses from randomized controlled trials demonstrated reduction of risk in the primary end point (adverse cardiovascular outcomes and/or all-cause mortality and/or HF hospitalization) with MRA use in the CKD subgroup (eGFR 30 to 60 mL/min/1.

Three recent large phase III randomized trials demonstrated a lack of survival benefit from intensive follow-up strategies in comparison with minimal follow-up.

Recently two randomized trials demonstrated the efficacy of local RT to prostate in metastatic prostate cancer patients (4,5).

BACKGROUND Prior replicate 12-week phase 3 trials demonstrated that once-daily doses of revefenacin inhalation solution at 88 μg and 175 μg produced significant bronchodilation over 24 h post dose in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Since the DAWN and DEFUSE 3 trials demonstrated the efficacy of EVT up to 24 hours after last seen well, CT angiography has become the operational standard for rapid accurate identification of intracranial LVO.

Field trials demonstrate the ability of these devices to collect quantitative in situ measurements of local sweat chloride concentration, local sweat loss (and sweat rate), and skin temperature during vigorous physical activity in controlled, indoor conditions and in open-ocean swimming.

Field trials demonstrated that the yield of the new Kasalath and TTP mutant lines was better than that of the wild type under modern cultivation and that the lines maintained the same desirable agronomic characteristics as their wild-type progenitors.

Phase III trials demonstrate that rituximab improves the OS in FL when combined with chemotherapy.

Objective Two randomized phase III trials demonstrated the efficacy and safety of combining bevacizumab with front-line carboplatin/paclitaxel for advanced ovarian cancer.

The initial trials demonstrated TAVR to be superior (PARTNER B) and noninferior (CoreValve Extreme Risk) to optimal medical therapy in inoperable patients.

Initial trials demonstrated potential benefit from transdermal nitroglycerin treatment early after symptom onset in patients with suspected stroke.

Recent trials demonstrated that mutation assays have a strong limitation in personalized selection of therapeutics, consequently, most of the drugs cannot be ranked and only a small percentage of patients can benefit from the screening.

Recent trials demonstrate the safety and efficacy of TAVR in low-risk patients and have led to an FDA indication for the use of TAVR in these patients.

These three trials demonstrated a similar range of weight loss, with the highest decrease level in Chinese trial.

Additionally, all three trials demonstrated a clear increase in risk for bleeding events.

On the other hand, the FAME and FAME-II trials demonstrated that revascularization guided by fractional flow reserve (FFR) significantly improves patient outcomes [22, 23].

Results Early results from three phase i/ii trials demonstrated that concurrent abiraterone acetate, adt, and rt is safe, improves the extent of chemical castration, and is associated with limited treatment failures.

Laboratory trials demonstrated that the final germination of conglomerated seed averaged 15% higher than control seed.

The observations from sea trials and laboratory trials demonstrate that laboratory emulators can be used in early stage development to identify the harmonic characteristics of a wave energy converter.

Recent large CV outcome trials demonstrated clear CV benefits of 2 novel classes of glucose-lowering agents (GLA), SGLT2 inhibitors and GLP-1 receptor agonists.

The LEADER and SUSTAIN-6 cardiovascular (CV) outcome trials demonstrated CV risk reduction for liraglutide and semaglutide in patients with type 2 diabetes (T2D).

None of the previous trials demonstrated any benefit of nalmefene on harm related to alcohol use, and the current study failed to show significant effect of nalmefene on health-related quality of life (i.

8501Background: Although previous trials demonstrated the efficacy and safety of postoperative cisplatin–based adjuvant chemotherapy for resected NSCLC, no phase III study has so far evaluated Pem/.

Several trials demonstrated that the process of inflammation may be responsible for initiation and progression of HF.

Although several trials demonstrated a significant decline in pain in VS groups during follow-up compared to baseline, without severe adverse events, the pooled analysis did not show VS was superior to placebo at any time windows [7–14 days: standardized mean difference (SMD): −0.

Recent major trials demonstrated sodium–glucose co-transporter-2 (SGLT2) inhibitors improve prognosis of T2DM patients through prevention of heart failure.

Of note, while no major trial exclusively enrolled elderly population, except for the Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly (ASPREE) trial [6], subgroup analyses from major trials demonstrated minimal heterogeneity in CV outcomes based on age (< 65 vs > 65 years) [4,7,8].

Both trials demonstrated that fluency remained stable in the presence of distraction.

Both trials demonstrated significant nephroprotection in patients with overt DKD (albuminuria >300 mg/g urinary creatinine) for combined primary endpoints of end-stage kidney disease (ESKD), doubling of serum creatinine or death from renal or cardiovascular causes in CREDENCE {hazard ratio [HR] 0.

These trials demonstrated absolute improvements in FEV1 (% predicted) at 24 weeks, MD 10.

These trials demonstrate that it reduces loco-regional recurrence, but has no impact on overall survival.

Pooled analysis of five trials demonstrated a protective effect on ulceration in streptokinase patients vs standard heparinization (OR, 0.

Four of the five trials demonstrated efficacy in reducing maternal anxiety, although the quality of evidence was low.

The results of the analysed clinical trials demonstrate efficiency of phytodrugs in treatment of mastalgia in  patients with various forms of diffusion mastopathy and premenstrual syndrome.

The results of the analysed clinical trials demonstrate efficiency of phytodrugs in treatment of mastalgia in patients with various forms of diffusion mastopathy and premenstrual syndrome.

However, recent trials demonstrate higher rates of device failure compared to contemporary drug-eluting stents.

However, recent trials demonstrate higher rates of scaffold thrombosis and device failure compared to conventional drug eluting stents.

Conclusion: Even though many pre-clinical trials demonstrate promising effects of different nutritional interventions on reducing brain injury and/or improving neurodevelopmental outcome, these positive effects have so far not evidently been demonstrated in RCTs.

Recent clinical trials demonstrate promising treatment strategies that likely impact clinical practice; including heart failure prevention with the use of SGLT2-inhibitors in patients with diabetes and cardiovascular risk, new treatments that may abrogate disease progression in cardiac amyloidosis, intravenous iron therapy in iron deficiency anemia in chronic systolic heart failure, predischarge treatment with angiotensin receptor blocker with neprilysin inhibition (ARNi) in patients hospitalized for acute decompensated heart failure, and newer continuous flow left ventricular assist device with increased durability and efficacy in patients with Stage D heart failure.